Cofactor Genomics

Cofactor Genomics is addressing the challenges in precision medicine through the development of predictive diagnostics, leveraging RNA and advanced Predictive Immune Modeling to create more effective biomarkers and ultimately improve patient outcomes. Founded by Jarret Glasscock and a team of experienced human genome scientists, Cofactor has pioneered a novel diagnostic technology. This technology is driven by unique and robust RNA data models built upon extensive data sets.

The organization's technology has undergone rigorous validation, including peer review by leading diagnostic technology standards bodies (CAP, AMP), with findings published in the Journal of Molecular Diagnostics. Furthermore, clinical studies presented by cancer physicians on the NCCN committee demonstrated the superiority of Cofactor's technology in predicting patient response to immunotherapy. This initial application targets a significant problem within the rapidly expanding immunotherapy sector, representing a total addressable market exceeding one billion dollars.

Building on recent achievements, Cofactor is expanding the application of its technology to encompass a broader range of cancers, targeting 50% of all cancer diagnoses in the United States. The company's investors include Menlo Ventures, DCVC, and Ascension Ventures, the investment arm of 13 national U.S. healthcare systems.